Biophytis shares are trading higher after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
Portfolio Pulse from Benzinga Newsdesk
Biophytis has signed a partnership with SEQENS to produce Sarconeos (BIO101), the company's main product. This has led to an increase in Biophytis' share prices.
July 18, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biophytis' shares are trading higher following the announcement of a partnership with SEQENS for the production of Sarconeos.
The partnership with SEQENS for the production of Sarconeos, Biophytis' main product, is a positive development for the company. This has led to an increase in the company's share prices, indicating investor confidence in the partnership's potential to boost the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100